Kairos Pharma, Ltd. (KAPA)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $1.54M
Last updated: Nov 17, 2026 at 11:03 AM ET
Kairos Pharma, Ltd. (KAPA) Stock Forecast
Analysts expect Kairos Pharma (KAPA) to earn -$2.59 per share in the fiscal year ending Dec 31, 2026. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$4.69.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$2.59
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$4.69
- EPS consensus
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$2.59 | -$2.59 to -$2.59 | 1 |
| Dec 31, 2027 | -$4.69 | -$4.69 to -$4.69 | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.64 | -$0.75 to -$0.51 | 4 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.66.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.59 | -$2.59 | -$2.59 | -$2.59 | -$2.66 | N/A |
| Fiscal year ending Dec 31, 2027 | -$4.69 | -$4.69 | -$4.69 | -$4.69 | -$3.82 | N/A |
Frequently Asked Questions About KAPA
What is the KAPA stock forecast?
Consensus analyst estimates put Kairos Pharma's EPS at -$2.59 for the fiscal year ending Dec 31, 2026.
What EPS do analysts expect from KAPA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.59, with estimates from -$2.59 to -$2.59 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.69, with estimates from -$4.69 to -$4.69 from 1 analyst.
How many analysts cover KAPA?
1 analyst estimates EPS for Kairos Pharma for the fiscal year ending Dec 31, 2026.
KAPA pages: Overview, Earnings, Forecast, Financials, Competitors